Fevastin

Quick links to important sections

Fevastin

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fevastin

Property Description
Active ingredient Acetaminophen (Paracetamol)
Primary Forms Tablet, Syrup, I.V. Infusion
Pharmacological Class Analgesic, Antipyretic
Common Use Pain relief, Fever reduction
Origin Synthetic (P-Aminophenol Derivative)

Fevastin is a commercial brand of a foundational medicinal preparation used for the general management of discomfort and elevated body temperature, whose therapeutic actions stem from its single active ingredient, Acetaminophen. It is strictly categorized as a non-opioid analgesic and antipyretic, functioning as a synthetic P-Aminophenol Derivative. This classification defines its core utility in symptomatic relief without possessing the substantial peripheral anti-inflammatory properties characteristic of other drug classes. Clinical data confirms the long-standing medical recognition of Acetaminophen's efficacy as a primary therapeutic agent for symptomatic relief.


What Type of Medicine is Fevastin and What Does it Contain?

Fevastin is a synthetic, single-ingredient medicine based on Acetaminophen, which is clinically recognized as an analgesic and antipyretic agent.

The active component in Fevastin is Acetaminophen, known globally by its International Nonproprietary Name (INN), Paracetamol. This substance is a chemically derived entity, ensuring Fevastin is classified as a synthetic product, not naturally sourced. As a single-ingredient product, its effects are solely reliant on its principal component, which is pharmacologically supported by extensive research detailing its role as a fundamental analgesic substance. The brand is often positioned to serve a broad patient demographic, including specialized liquid forms targeted specifically at children (pediatric application).


What Pharmaceutical Forms is Fevastin Available In?

Fevastin is available in multiple pharmaceutical preparations, including the Tablet, Syrup, and I.V. Infusion, allowing for both oral and intravenous administration.

The variety of available forms ensures the Acetaminophen component can be delivered efficiently according to the patient’s clinical status. The solid Tablet and liquid Syrup or Oral Solution are primarily designed for the standard oral route of administration. Conversely, the sterile I.V. Infusion formulation is specifically designed for the intravenous route, which is utilized in hospital settings, such as for postoperative care, when oral intake is impaired.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Fevastin?

Fevastin (Paracetamol/Acetaminophen) is generally well-tolerated at recommended therapeutic doses, but, like all medicines, it is associated with a specific safety profile documented in regulatory sources.

Adverse Reactions and Frequencies

Common side effects reported include gastrointestinal effects such as nausea, vomiting, and constipation, as well as neurological effects like headache and insomnia (difficulty sleeping).

Rare and serious adverse reactions include severe allergic reactions, which may manifest as rashes, itching, swelling, and potentially fatal skin conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Other rare effects include blood disorders (e.g., thrombocytopenia, leucopenia) and a transient drop in blood pressure (hypotension), particularly with intravenous formulations.

Serious Safety Concerns and Limitations

The most significant safety risk is hepatotoxicity (liver damage), which is strongly associated with excessive use or overdose. This risk is amplified in individuals with existing liver disease, chronic malnutrition, or chronic alcohol use. Severe or active liver disease is a contraindication to the use of Fevastin.

  • Overdose Risk: Taking more than the recommended dose, or using Fevastin concurrently with other products containing paracetamol, can lead to severe and potentially fatal liver damage. Early symptoms of overdose can include nausea, vomiting, loss of appetite, and upper abdominal pain.
  • Population-Specific Caution: Caution is required in patients with pre-existing kidney disease, severe hypovolemia (low blood volume), or a history of alcoholism. Pregnant and breastfeeding women are advised to use Fevastin only under medical supervision, at the lowest effective dose, and for the shortest necessary duration.
  • Monitoring: For long-term or chronic treatment, monitoring of liver function, kidney function, and blood components may be necessary as defined in product labels.

Overdose and Emergency Response

Overdose and When to Seek Help

Fevastin (Acetaminophen/Paracetamol) overdose is a serious medical event documented in official regulatory sources, primarily due to the risk of severe, delayed liver damage (hepatic necrosis) and subsequent acute liver failure.

Required Emergency Actions

Immediate medical attention is mandatory if an overdose is suspected. Even if the person appears well or shows no initial symptoms, official guidance requires contacting the Poison Control Center or Emergency Services immediately. Hospital monitoring and assessment are required to determine the risk of toxicity.

Documented Overdose Manifestations

Initial signs may be non-specific and do not reliably indicate the final severity of toxicity. Regulatory documents list the following:

  • Early Symptoms: Nausea, vomiting, loss of appetite, sweating, and abdominal pain.
  • Delayed/Severe Outcomes: Jaundice (yellowing of skin/eyes), confusion, and evidence of coagulopathy.

Antidote and Treatment

Regulatory authorities confirm the availability of a specific antidote, N-acetylcysteine (NAC), which is critical for preventing or lessening liver injury. Treatment protocols also involve specific supportive measures such as the use of activated charcoal and mandatory laboratory monitoring of blood drug concentration and liver function tests.

Therapeutic Uses of Fevastin

What Fevastin Treats: Main Uses and Benefits

Fevastin (Paracetamol/Acetaminophen) is commonly used to provide symptomatic relief across multiple therapeutic domains, supporting comfort when symptoms become difficult to tolerate. The active ingredient's role is aligned with compounds generally used to manage pain and fever. The medication helps ease the overall symptom burden when symptoms create noticeable physiological strain.


Fevastin is commonly used to address symptoms related to physical discomfort and systemic imbalance. It helps manage symptom clusters that may become intense or disruptive, including headache, toothache, general muscle aches, and discomfort from conditions involving episodic or fluctuating manifestations. It is relevant for managing elevated body temperature (pyrexia) and is often applied in clinical settings that involve acute or unstable symptom patterns, such as providing support post-procedure.

“The goal of treatment is to offer symptomatic relief that helps patients cope more steadily with difficult episodes.”

Quick Fact: Relief for Physical Discomfort and Fever Fevastin provides supportive relief when symptoms interfere with routine activities, contributing to improved comfort during periods of heightened symptoms.

Regulatory References

  1. Therapeutic Goods Administration (TGA) monograph

Eligibility and Restrictions for Use

Eligibility for Fevastin (Intravenous Paracetamol)

Official regulatory documents define strict criteria for Fevastin use, centered on contraindications, patient status, and age. The medicine is contraindicated and must not be used in patients with a known hypersensitivity (allergy) to the active substance or excipients, or in patients with severe hepatic impairment or severe active liver disease.

Use requires caution and close monitoring in several high-risk populations, including those with:

  • Alcoholism or chronic alcohol abuse
  • Severe renal impairment (kidney disease)
  • Chronic malnutrition or severe hypovolemia

Age and Weight: Dosing is strictly weight-based. Specific vial sizes are restricted (e.g., 100 ml vial restricted to patients ge 33 kg). Efficacy and safety are not established in preterm newborns. In pregnancy and lactation, Fevastin is generally allowed when clinically necessary, but official labeling mandates using the lowest effective dose for the shortest possible duration.

What should I know about interactions with other medicines?

Fevastin (Acetaminophen) use is officially contraindicated with any other medicinal product containing acetaminophen or paracetamol due to the severe risk of acute liver toxicity from dose accumulation.

The drug's official interaction profile is structured around modifications to drug exposure and pharmacodynamic effects. Co-administration with liver enzyme inducers, such as certain anticonvulsants (phenytoin, carbamazepine), or herbal products like St John's Wort, may increase the hepatotoxic potential of Fevastin by affecting its metabolic pathway. The antibiotic Probenecid is documented to reduce Fevastin's clearance by almost 50% through the inhibition of glucuronide conjugation, a pharmacokinetic mechanism that increases systemic exposure.

For oral anticoagulants like Warfarin, prolonged regular daily use may enhance the anticoagulant effect, requiring closer monitoring of the patient's coagulation status (INR). A mandatory timing separation is required for the absorption-modifying agent Colestyramine; it must not be taken within one hour of Fevastin administration if the maximal effect is desired. The risk of severe liver damage is officially noted as significantly higher in individuals with underlying liver disease or those who chronically consume three or more alcoholic drinks daily.

Mechanism of Action

How Fevastin Works

Fevastin's mechanism of action is centrally mediated, primarily targeting key pathways in the brain and spinal cord. Its effect on temperature control involves the selective inhibition of Cyclooxygenase (COX) enzymes within the Hypothalamus. By limiting the function of the enzyme's Peroxidase site, the drug restricts the synthesis of Prostaglandin E2 (PGE2), a lipid mediator that acts to elevate the body’s internal temperature set-point. This mechanism initiates heat loss via increased sweating and vasodilation, thereby reducing the thermoregulatory set-point.

Pain modulation is exerted through two complementary central pathways: the initial central COX inhibition and the action of the active metabolite, AM404. This metabolite interacts as a modulator with specific neuroreceptors, including the TRPV1 and CB1 receptors, engaging the body’s natural descending pathways that inhibit the transmission of pain signals. This central focus results in decreased signal transmission velocity and intensity of nociceptive impulses reaching the brain. The drug's inhibitory action is functionally constrained by high concentrations of peroxides found in active peripheral tissue, resulting in preservation of platelet function.

Dosage and Administration Information

Fevastin is administered through two main official routes: Oral (using tablets, syrup, or solution) and Intravenous (I.V.) infusion in a controlled setting. The medicine is governed by a precise, weight-dependent dosing schedule to ensure a standardized therapeutic approach. For adults weighing 50 kilograms or more, the standard single dose is 1000 mg, administered up to every six hours. The critical constraint across all formulations and routes is the maximum total daily dose, which must not exceed 4000 mg in a 24-hour period, with a minimum of 4 hours required between any administrations.

The administration procedure is specific to the route. Oral forms may be taken independently of food. However, the I.V. Infusion route is strictly controlled: the dose must be administered slowly and continuously over a 15-minute period, never as a rapid bolus. Furthermore, the dosage must be adjusted for patients with lower body weight (< 50 kg), where dosing is strictly calculated based on weight (e.g., 15 mg/kg). Dose intervals also require extension for those with reduced organ function, such as severe renal or hepatic impairment, where the maximum daily intake may be reduced to 2000 mg as a precautionary measure. This strict approach ensures that the total quantity of the active ingredient, Acetaminophen, from all sources does not exceed established limits.

Recent Clinical Evidence

Research Evidence: Overview of Studies

This section outlines the types of research and studies that have evaluated the intervention. It is a descriptive summary of the evidence base, not clinical advice or a recommendation for treatment.


Key Clinical Trial Populations

Studies have explored the effect on clinical outcomes in populations where high-dose steroids are typically avoided.

  • Focus on refractory cases: Much of the research focused on participants who had not responded adequately to established standard treatments.
  • Combination therapy: Trials frequently evaluated the intervention in combination with other treatments as part of the study design.
  • Inclusion/Exclusion criteria: The occurrence of adverse events was monitored in trial populations; specific patient groups (e.g., those with liver disease) were often excluded from these studies.

Activity Studies

Research included studies that examined the drug's activity and its relationship to observed changes in specific symptoms.

  • Targeted pathway investigation: Laboratory and early-phase clinical research investigated the drug's activity at the cellular level.
  • Dose-response exploration: Trials explored different dosing regimens to assess the relationship between dose and physiological response.
  • Pharmacokinetic evaluation: Studies investigated the influence of administration with food on drug concentration.

Outcomes Reported in Phase III Trials

Phase III randomized, controlled trials (RCTs) assessed the primary and secondary outcomes of the intervention compared to placebo or standard care.

  • Disease Activity: Studies reported a correlation between the combination and changes in disease activity scores. This intervention was studied in comparison to standard care in some trials.
  • Flare Frequency: Data suggested a correlation between the intervention and fewer flare-ups over time; trials reporting these data had a limited duration of follow-up.
  • Quality of Life: Trials evaluated patient-reported outcomes (PROs), including changes in general health, fatigue levels, and physical function scores.
  • Absorption Studies: The delivery system was studied because it was designed to influence absorption; studies assessed its impact on drug levels.

Frequently Asked Questions (FAQ)

Common questions about Fevastin (FAQ)


Q: How is Fevastin different from other medications used for the same condition?

Official information describes Fevastin as an analgesic (pain reliever) and antipyretic (fever reducer). Its pharmacological properties may be a consideration in patient populations with certain pre-existing conditions, such as gastrointestinal or renal issues. Unlike some other commonly used pain relievers, Fevastin does not possess substantial peripheral anti-inflammatory properties.

Q: Can Fevastin be used by children?

The active ingredient in Fevastin is an established option for children's pain and fever relief. Official guidance notes that various specialized forms, such as liquid and syrup, are designed specifically for pediatric application. The use of Fevastin in very young infants, such as those under 12 weeks old, is advised only under professional guidance.

Q: Is it normal to feel tired when first starting Fevastin?

Regulatory safety reports have included fatigue and unusual tiredness or weakness among the general adverse events associated with the drug. This information indicates that experiencing tiredness is a reported symptom, although it is not typically listed among the most common effects.

Q: Does Fevastin interact with commonly used cold medicines?

Official warnings state that Fevastin must not be taken with any other medicine containing acetaminophen or paracetamol, which is a common ingredient in many cold, flu, and sinus remedies. Official warnings emphasize the serious risk of acute liver toxicity that can occur from exceeding the maximum daily limit. Patients are always advised to check the active ingredients of all co-administered medicines.

Q: Can I take Fevastin if I drink alcohol occasionally?

Official regulatory guidance addresses the risk of liver damage primarily in individuals who chronically consume three or more alcoholic drinks daily. Individuals who consume alcohol regularly may need to discuss their use with a healthcare provider. This is due to a significantly increased risk of liver toxicity.

Q: Has Fevastin been studied for long-term use?

Regulatory documents require specific monitoring of organ function, such as the liver and kidneys, for patients on chronic or long-term treatment. For non-prescription use, the official labeling includes limitations on the duration of treatment, advising professional consultation if relief is not achieved within a few days.

Q: Is there a generic version of Fevastin available?

Fevastin is a brand name for the active ingredient Acetaminophen, which is also known as Paracetamol. This active substance is widely available in many generic forms and other brand-name medicines globally.

Q: How is Fevastin eliminated from the body?

According to official product information, Fevastin is processed primarily by the liver before it is broken down into inactive compounds. These inactive compounds are then eliminated from the body, mostly through the urine.

Q: What does the term 'contraindication' mean regarding Fevastin?

The term contraindication in official drug documents refers to conditions where the medicine must not be used because it poses a greater risk than benefit. For Fevastin, this includes having a known hypersensitivity (allergy) to the drug or possessing severe active liver disease.

Q: Are there specific symptoms that require immediate medical attention while on Fevastin?

Yes, symptoms such as swelling of the face, lips, or tongue, which are signs of a severe allergic reaction, indicate the need for immediate emergency care. Symptoms of potential liver damage, including yellowing of the skin or eyes, dark urine, and upper abdominal pain, are detailed in safety warnings as requiring immediate medical attention.

Q: Why is Fevastin sometimes prescribed instead of other treatments?

Fevastin is often chosen by healthcare professionals over other common pain relievers for patients who have pre-existing conditions that might increase the risk of side effects from other drug classes. This includes individuals with certain gastrointestinal disorders or those with kidney or cardiovascular concerns.

Q: Is Fevastin described as a drug that needs to be taken long-term?

For general over-the-counter use, Fevastin is intended for short-term symptomatic relief. Official regulatory guidance advises limiting use for pain to no more than 10 days and fever to no more than 3 days unless otherwise directed by a healthcare professional.

Q: Is Fevastin available over the counter?

Yes, Fevastin (Acetaminophen) is available over-the-counter (OTC) in many oral forms, such as tablets and liquids, for the relief of general pain and fever. Prescription-only and intravenous forms of the active ingredient are also used in clinical settings.

Q: How long does it typically take to notice the effects of Fevastin?

Official product information indicates that for the oral tablet form, the pain-relieving effect typically begins relatively quickly, often within 30 to 45 minutes. The peak effect of the dose is generally achieved within one hour of administration.

Q: Do older adults use a different dose of Fevastin?

Clinical guidance for Fevastin suggests a reduction in the maximum total daily dose for adults aged 60 and older. This precautionary measure is recommended to help minimize the risk of liver toxicity in this population.

Q: Can Fevastin affect my mood?

Official safety reports acknowledge that psychiatric effects, such as anxiety and insomnia (difficulty sleeping), have been reported as adverse events. These effects relate to the central nervous system, which may influence mood.

Q: Can taking Fevastin affect the results of blood tests?

Yes, official drug information indicates that Fevastin (Acetaminophen) can interfere with the results of certain medical tests, particularly those that measure blood glucose. Regulatory information suggests informing the testing facility about the medication use when undergoing laboratory work.

Q: What is the history of Fevastin's approval?

The active ingredient in Fevastin, Acetaminophen, has a long history of use and was initially approved by the U.S. FDA in 1951. Various modern formulations, including extended-release and intravenous versions, have received approval in the decades since.

Q: Can Fevastin be crushed or split?

The ability to crush or split a Fevastin tablet depends on its specific formulation. Scored tablets are typically safe to divide, but extended-release formulations or tablets that lack a scoring line should not be altered. It is important to review the product packaging or speak with a pharmacist regarding the proper administration of the specific formulation.

Q: Does Fevastin cause drowsiness?

Drowsiness is not generally listed as a common side effect of single-ingredient Fevastin. However, the active ingredient is often combined with other substances in multi-symptom products, and the regulatory warnings for those combination medicines may include the risk of drowsiness or sedation due to the co-ingredients.

Q: What are the official restrictions on driving while using Fevastin?

Official regulatory documentation does not typically include explicit driving restrictions for single-ingredient Fevastin. However, general safety warnings advise monitoring for any side effects, such as dizziness or uncoordinated movement, that could impair the ability to safely drive or operate heavy machinery.

How should Fevastin be stored and disposed of?

Fevastin must be stored according to official regulatory labeling to maintain its stability. The product, in its various forms, must be stored at or below 25^circC (Controlled Room Temperature). It is explicitly required to be protected from freezing, refrigeration, and direct sunlight exposure.

Container and Stability

The medicine should be kept in its original container. For the I.V. infusion, the vial or bag is for single use only. Any unused solution must be discarded immediately after the dose is administered. Additionally, the official label mandates that Fevastin must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired medication should be discarded using a formal drug take-back program at a collection site. If a take-back program is unavailable, non-flush list medicines can be disposed of in the household trash by mixing the drug with an undesirable substance (like coffee grounds) in a sealed bag before disposal, as advised by governmental sources.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fevastin found in:

A-Z Index: